-
公开(公告)号：WO2007053151A1
公开(公告)日：2007-05-10
申请号：PCT/US2005/040342
申请日：2005-11-07
申请人： MANNKIND CORPORATION , PATTERSON, John, Bruce , VOLKMANN, Kori, Shallyn , BRUMM, Duane , STILES, caryn, Bess
CPC分类号： C12Q1/34 , C12Q1/6818 , C12Q2525/301 , C12Q2521/301
摘要： IRE-1α substrates useful for identifying agonists and antagonists of IRE-1α Rnase activity.
摘要翻译： IRE-1a底物可用于鉴定IRE-1a Rnase活性的激动剂和拮抗剂。
-
公开(公告)号：WO2011127070A2
公开(公告)日：2011-10-13
申请号：PCT/US2011/031274
申请日：2011-04-05
申请人： MANNKIND CORPORATION , ZENG, Qingping , TORO, Andras , PATTERSON, John, Bruce , WADE, Warren, Stanfield , ZUBOVICS, Zoltan , YANG, Yun , WU, Zhipeng
发明人： ZENG, Qingping , TORO, Andras , PATTERSON, John, Bruce , WADE, Warren, Stanfield , ZUBOVICS, Zoltan , YANG, Yun , WU, Zhipeng
IPC分类号： A61K31/343 , A61K31/352 , A61K31/37 , A61K31/381 , A61K31/4025 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4172 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/4433 , A61K31/4439 , A61K31/452 , A61K31/453 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K45/06 , A61P35/00 , A61P31/12 , A61P37/02
CPC分类号： A61K31/366 , A61K31/343 , A61K31/352 , A61K31/37 , A61K31/381 , A61K31/4025 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4172 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/4433 , A61K31/4439 , A61K31/452 , A61K31/453 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D217/02 , C07D217/08 , C07D311/12 , C07D311/16 , C07D311/20 , C07D311/22 , C07D311/94 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/10 , C07D409/04 , C07D417/04 , Y02A50/389 , Y02A50/393
摘要： Compounds which directly inhibit IRE-1α activity in vitro , prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
摘要翻译： 在体外直接抑制IRE-1a活性的化合物，前药和药学上可接受的盐。 这样的化合物和前药可用于治疗与未折叠的蛋白质应答相关的疾病或具有调节的IRE1依赖性衰变（RIDD）的疾病，并可用作单一药剂或联合疗法。
-
公开(公告)号：WO2011056744A4
公开(公告)日：2011-07-14
申请号：PCT/US2010054940
申请日：2010-11-01
IPC分类号： A61K31/185 , A61K31/27
CPC分类号： C07D487/08 , C07C59/74 , C07C65/30 , C07C69/738 , C07C235/78 , C07C235/84 , C07D207/08 , C07D207/14 , C07D207/16 , C07D211/26 , C07D211/58 , C07D211/62 , C07D211/66 , C07D211/98 , C07D213/36 , C07D213/38 , C07D213/74 , C07D213/81 , C07D213/82 , C07D239/26 , C07D239/38 , C07D249/06 , C07D263/34 , C07D277/12 , C07D277/18 , C07D277/42 , C07D277/56 , C07D295/108 , C07D295/112 , C07D295/185 , C07D295/192 , C07D295/26 , C07D295/32 , C07D307/68 , C07D333/38 , C07D333/40 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/06 , C07D405/12 , C07D409/12 , C07D413/06 , C07D417/04 , C07D417/06 , C07D417/12
摘要： The invention provides compounds which directly inhibit IRE-1a activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
摘要翻译： 本发明提供了直接抑制体外IRE-1a活性的化合物，其前体药物和药学上可接受的盐。 此类化合物和前药可用于治疗与未折叠的蛋白质应答有关的疾病，并可用作单一药剂或组合疗法。
-
公开(公告)号：WO2011127070A3
公开(公告)日：2012-04-19
申请号：PCT/US2011031274
申请日：2011-04-05
申请人： MANNKIND CORP , ZENG QINGPING , TORO ANDRAS , PATTERSON JOHN BRUCE , WADE WARREN STANFIELD , ZUBOVICS ZOLTAN , YANG YUN , WU ZHIPENG
发明人： ZENG QINGPING , TORO ANDRAS , PATTERSON JOHN BRUCE , WADE WARREN STANFIELD , ZUBOVICS ZOLTAN , YANG YUN , WU ZHIPENG
IPC分类号： A61K31/343 , A61K31/352 , A61K31/37 , A61K31/381 , A61K31/4025 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4172 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/4433 , A61K31/4439
CPC分类号： A61K31/366 , A61K31/343 , A61K31/352 , A61K31/37 , A61K31/381 , A61K31/4025 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4172 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/4433 , A61K31/4439 , A61K31/452 , A61K31/453 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D217/02 , C07D217/08 , C07D311/12 , C07D311/16 , C07D311/20 , C07D311/22 , C07D311/94 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/10 , C07D409/04 , C07D417/04
摘要： Compounds which directly inhibit IRE-1a activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
摘要翻译： 在体外直接抑制IRE-1a活性的化合物，前药和药学上可接受的盐。 这样的化合物和前药可用于治疗与未折叠的蛋白质应答相关的疾病或具有调节的IRE1依赖性衰变（RIDD）的疾病，并可用作单一药剂或联合疗法。
-
公开(公告)号：WO2011056744A1
公开(公告)日：2011-05-12
申请号：PCT/US2010/054940
申请日：2010-11-01
IPC分类号： A61K31/185 , A61K31/27
CPC分类号： C07D487/08 , C07C59/74 , C07C65/30 , C07C69/738 , C07C235/78 , C07C235/84 , C07D207/08 , C07D207/14 , C07D207/16 , C07D211/26 , C07D211/58 , C07D211/62 , C07D211/66 , C07D211/98 , C07D213/36 , C07D213/38 , C07D213/74 , C07D213/81 , C07D213/82 , C07D239/26 , C07D239/38 , C07D249/06 , C07D263/34 , C07D277/12 , C07D277/18 , C07D277/42 , C07D277/56 , C07D295/108 , C07D295/112 , C07D295/185 , C07D295/192 , C07D295/26 , C07D295/32 , C07D307/68 , C07D333/38 , C07D333/40 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/06 , C07D405/12 , C07D409/12 , C07D413/06 , C07D417/04 , C07D417/06 , C07D417/12
摘要： The invention provides compounds which directly inhibit IRE-1α activity in vitro , prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
摘要翻译： 本发明提供了在体外直接抑制IRE-1a活性的化合物，其前药和药学上可接受的盐。 这样的化合物和前药可用于治疗与未折叠的蛋白质应答相关的疾病，并可用作单一药剂或联合疗法。
-
公开(公告)号：WO2008154484A1
公开(公告)日：2008-12-18
申请号：PCT/US2008/066310
申请日：2008-06-09
IPC分类号： C07C47/54 , C07C47/548 , C07D213/24 , C07D215/12 , C07D217/14 , C07D295/00 , C07D333/10 , C07D275/03 , A61K31/33
CPC分类号： C07C65/21 , A61K31/11 , A61K31/135 , A61K31/166 , A61K31/192 , A61K31/357 , A61K31/381 , A61K31/505 , A61K31/5375 , A61K31/5377 , C07C47/55 , C07C47/565 , C07C47/575 , C07C65/11 , C07C65/26 , C07C65/30 , C07C205/44 , C07C205/61 , C07C223/02 , C07C233/65 , C07C235/42 , C07C235/84 , C07C251/24 , C07C317/24 , C07C321/04 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/48 , C07D213/64 , C07D213/69 , C07D213/74 , C07D215/14 , C07D217/16 , C07D231/12 , C07D235/08 , C07D239/26 , C07D239/54 , C07D241/18 , C07D249/18 , C07D261/08 , C07D277/34 , C07D295/125 , C07D295/15 , C07D295/192 , C07D307/80 , C07D317/54 , C07D319/08 , C07D319/18 , C07D321/10 , C07D333/22 , C07D333/58 , C07D401/12 , C07D403/12 , C07D417/10 , Y02A50/389 , Y02A50/393
摘要： Compounds which directly inhibit IRE-lα activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
摘要翻译： 在体外直接抑制IRE-1a活性的化合物，其前药和药学上可接受的盐。 这样的化合物和前药可用于治疗与未折叠的蛋白质应答相关的疾病，并可用作单一药剂或联合疗法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.017 秒)
